Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

56,287 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Durvalumab plus tremelimumab alone or in combination with low-dose or hypofractionated radiotherapy in metastatic non-small-cell lung cancer refractory to previous PD(L)-1 therapy: an open-label, multicentre, randomised, phase 2 trial.
Schoenfeld JD, Giobbie-Hurder A, Ranasinghe S, Kao KZ, Lako A, Tsuji J, Liu Y, Brennick RC, Gentzler RD, Lee C, Hubbard J, Arnold SM, Abbruzzese JL, Jabbour SK, Uboha NV, Stephans KL, Johnson JM, Park H, Villaruz LC, Sharon E, Streicher H, Ahmed MM, Lyon H, Cibuskis C, Lennon N, Jhaveri A, Yang L, Altreuter J, Gunasti L, Weirather JL, Mak RH, Awad MM, Rodig SJ, Chen HX, Wu CJ, Monjazeb AM, Hodi FS. Schoenfeld JD, et al. Among authors: lee c. Lancet Oncol. 2022 Feb;23(2):279-291. doi: 10.1016/S1470-2045(21)00658-6. Epub 2022 Jan 13. Lancet Oncol. 2022. PMID: 35033226 Free PMC article. Clinical Trial.
Induction chemotherapy with carboplatin, irinotecan, and paclitaxel followed by high dose three-dimension conformal thoracic radiotherapy (74 Gy) with concurrent carboplatin, paclitaxel, and gefitinib in unresectable stage IIIA and stage IIIB non-small cell lung cancer.
Stinchcombe TE, Morris DE, Lee CB, Moore DT, Hayes DN, Halle JS, Rivera MP, Rosenman JG, Socinski MA. Stinchcombe TE, et al. J Thorac Oncol. 2008 Mar;3(3):250-7. doi: 10.1097/JTO.0b013e3181653cf4. J Thorac Oncol. 2008. PMID: 18317067 Free article. Clinical Trial.
Long-term follow-up of a phase I/II trial of dose escalating three-dimensional conformal thoracic radiation therapy with induction and concurrent carboplatin and paclitaxel in unresectable stage IIIA/B non-small cell lung cancer.
Stinchcombe TE, Lee CB, Moore DT, Rivera MP, Halle J, Limentani S, Rosenman JG, Socinski MA. Stinchcombe TE, et al. J Thorac Oncol. 2008 Nov;3(11):1279-85. doi: 10.1097/JTO.0b013e31818b1971. J Thorac Oncol. 2008. PMID: 18978563 Free article. Clinical Trial.
A randomized phase II trial of first-line treatment with gemcitabine, erlotinib, or gemcitabine and erlotinib in elderly patients (age ≥70 years) with stage IIIB/IV non-small cell lung cancer.
Stinchcombe TE, Peterman AH, Lee CB, Moore DT, Beaumont JL, Bradford DS, Bakri K, Taylor M, Crane JM, Schwartz G, Hensing TA, McElroy E Jr, Niell HB, Harper HD, Pal S, Socinski MA. Stinchcombe TE, et al. J Thorac Oncol. 2011 Sep;6(9):1569-77. doi: 10.1097/JTO.0b013e3182210430. J Thorac Oncol. 2011. PMID: 21716146 Free article. Clinical Trial.
A retrospective analysis of VeriStrat status on outcome of a randomized phase II trial of first-line therapy with gemcitabine, erlotinib, or the combination in elderly patients (age 70 years or older) with stage IIIB/IV non-small-cell lung cancer.
Stinchcombe TE, Roder J, Peterman AH, Grigorieva J, Lee CB, Moore DT, Socinski MA. Stinchcombe TE, et al. J Thorac Oncol. 2013 Apr;8(4):443-51. doi: 10.1097/JTO.0b013e3182835577. J Thorac Oncol. 2013. PMID: 23370367 Free article. Clinical Trial.
56,287 results
You have reached the last available page of results. Please see the User Guide for more information.